Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis

International Immunopharmacology

Volumn 35, Issue , 2016, Pages 301-306

  Kasama, Tsuyoshi ^a,b   Isozaki, Takeo ^a   Takahashi, Ryo ^a   Miwa, Yusuke ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

Author keywords

Biologics; Cytokines; IL 6; Immunological factors; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ADIPOCYTOKINE; CYTOKINE; INTERFERON; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; TOCILIZUMAB; VASCULOTROPIN; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

HUMAN; LYMPHOCYTE DIFFERENTIATION; OSTEOCLASTOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; ANIMAL; ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; DRUG EFFECTS; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; CYTOKINES; HUMANS; INTERLEUKIN-6; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84963555190     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.03.016     Document Type: Review

References (88)

1. F. Brennan, and J. Beech Update on cytokines in rheumatoid arthritis Curr. Opin. Rheumatol. 19 2007 296 301
2. Z. Szekanecz, A. Vegvari, Z. Szabo, and A.E. Koch Chemokines and chemokine receptors in arthritis Front. Biosci. (Schol Ed) 2 2010 153 167
3. I.B. McInnes, and G. Schett The pathogenesis of rheumatoid arthritis N. Engl. J. Med. 365 2011 2205 2219
4. G.R. Burmester, E. Feist, and T. Dorner Emerging cell and cytokine targets in rheumatoid arthritis Nat. Rev. Rheumatol. 10 2014 77 88
5. J.S. Smolen, and R.N. Maini Interleukin-6: a new therapeutic target Arthritis Res. Ther. 8 Suppl. 2 2006 S5
6. N. Nishimoto, and T. Kishimoto Interleukin 6: from bench to bedside Nat. Clin. Pract. Rheumatol. 2 2006 619 626
7. X. Liu, A.J. Teichtahl, and I.P. Wicks Interleukin-6 in rheumatoid arthritis - from the laboratory to the bedside Curr. Pharm. Des. 21 2015 2187 2197
8. I.B. McInnes, and J.R. O'Dell State-of-the-art: rheumatoid arthritis Ann. Rheum. Dis. 69 2010 1898 1906
9. J.S. Smolen, A. Beaulieu, A. Rubbert-Roth, C. Ramos-Remus, J. Rovensky, E. Alecock, and et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 371 2008 987 997
10. P. Emery, E. Keystone, H.P. Tony, A. Cantagrel, R. van Vollenhoven, A. Sanchez, and et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Ann. Rheum. Dis. 67 2008 1516 1523
11. R.M. Fleischmann, A.M. Halland, M. Brzosko, R. Burgos-Vargas, C. Mela, E. Vernon, and et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results J. Rheumatol. 40 2013 113 126
12. G.R. Burmester, A. Rubbert-Roth, A. Cantagrel, S. Hall, P. Leszczynski, D. Feldman, and et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study) Ann. Rheum. Dis. 73 2014 69 74
13. A. Ogata, K. Amano, H. Dobashi, M. Inoo, T. Ishii, T. Kasama, and et al. Longterm safety and efficacy of subcutaneous tocilizumab monotherapy: results from the 2-year open-label extension of the MUSASHI study J. Rheumatol. 2015
14. C. Gabay, P. Emery, R. van Vollenhoven, A. Dikranian, R. Alten, K. Pavelka, and et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial Lancet 381 2013 1541 1550
15. J.S. Smolen, R. Landewe, F.C. Breedveld, M. Buch, G. Burmester, M. Dougados, and et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Ann. Rheum. Dis. 73 2014 492 509
16. S. Akira, T. Taga, and T. Kishimoto Interleukin-6 in biology and medicine Adv. Immunol. 54 1993 1 78
17. F. Schaper, and S. Rose-John Interleukin-6: biology, signaling and strategies of blockade Cytokine Growth Factor Rev. 26 2015 475 487
18. T. Hirano, T. Matsuda, T. Turner, N. Miyasaka, G. Buchan, B. Tang, and et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis Eur. J. Immunol. 18 1988 1797 1801
19. T. Alonzi, E. Fattori, D. Lazzaro, P. Costa, L. Probert, G. Kollias, and et al. Interleukin 6 is required for the development of collagen-induced arthritis J. Exp. Med. 187 1998 461 468
20. T. Naka, N. Nishimoto, and T. Kishimoto The paradigm of IL-6: from basic science to medicine Arthritis Res. 4 Suppl. 3 2002 S233 S242
21. U. Sack, R.W. Kinne, T. Marx, P. Heppt, S. Bender, and F. Emmrich Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis Rheumatol. Int. 13 1993 45 51
22. S. Kotake, K. Sato, K.J. Kim, N. Takahashi, N. Udagawa, I. Nakamura, and et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation J. Bone Miner. Res. 11 1996 88 95
23. J.R. Jackson, J.A.L. Minton, M.L. Ho, N. Wei, and J.D. Winkler Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1b J. Rheumatol. 24 1997 1253 1259
24. P. Ben-Av, L.J. Crofford, R.L. Wilder, and T. Hla Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis FEBS Lett. 372 1995 83 87
25. E. Bettelli, Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka, and et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Nature 441 2006 235 238
26. I. Caiello, G. Minnone, D. Holzinger, T. Vogl, G. Prencipe, A. Manzo, and et al. IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases PLoS One 9 2014 e107886
27. A. Kuryliszyn-Moskal Cytokines and soluble CD4 and CD8 molecules in rheumatoid arthritis: relationship to systematic vasculitis and microvascular capillaroscopic abnormalities Clin. Rheumatol. 17 1998 489 495
28. K. Nistala, and L.R. Wedderburn Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis Rheumatology (Oxford) 48 2009 602 606
29. A. Alunno, M. Manetti, S. Caterbi, L. Ibba-Manneschi, O. Bistoni, E. Bartoloni, and et al. Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications Mediat. Inflamm. 2015 2015 751793
30. T. Korn, M. Mitsdoerffer, A.L. Croxford, A. Awasthi, V.A. Dardalhon, G. Galileos, and et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3 + regulatory T cells Proc. Natl. Acad. Sci. U. S. A. 105 2008 18460 18465
31. C.A. Lawson, A.K. Brown, V. Bejarano, S.H. Douglas, C.H. Burgoyne, A.S. Greenstein, and et al. Early rheumatoid arthritis is associated with a deficit in the CD4 + CD25high regulatory T cell population in peripheral blood Rheumatology (Oxford) 45 2006 1210 1217
32. M. Samson, S. Audia, N. Janikashvili, M. Ciudad, M. Trad, J. Fraszczak, and et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis Arthritis Rheum. 64 2012 2499 2503
33. J. Kikuchi, M. Hashizume, Y. Kaneko, K. Yoshimoto, N. Nishina, and T. Takeuchi Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response Arthritis Res. Ther. 17 2015 10
34. B. Pesce, L. Soto, F. Sabugo, P. Wurmann, M. Cuchacovich, M.N. Lopez, and et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients Clin. Exp. Immunol. 171 2013 237 242
35. J. Lubbers, M. Brink, L.A. van de Stadt, S. Vosslamber, J.G. Wesseling, D. van Schaardenburg, and et al. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis Ann. Rheum. Dis. 72 2013 776 780
36. J. Rodriguez-Carrio, P. Lopez, and A. Suarez Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine Clin. Sci. 128 2015 449 464 (London, England: 1979)
37. Y. Mitani, A. Takaoka, S.H. Kim, Y. Kato, T. Yokochi, N. Tanaka, and et al. Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling Genes Cells 6 2001 631 640
38. L.B. Ivashkiv Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis Autoimmunity 36 2003 473 479
39. T.C. van der Pouw Kraan, C.A. Wijbrandts, L.G. van Baarsen, A.E. Voskuyl, F. Rustenburg, J.M. Baggen, and et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients Ann. Rheum. Dis. 66 2007 1008 1014
40. C.P. Mavragani, D.T. La, W. Stohl, and M.K. Crow Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort Arthritis Rheum. 62 2010 392 401
41. R.M. Thurlings, M. Boumans, J. Tekstra, J.A. van Roon, K. Vos, D.M. van Westing, and et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients Arthritis Rheum. 62 2010 3607 3614
42. Y. Sanayama, K. Ikeda, Y. Saito, S. Kagami, M. Yamagata, S. Furuta, and et al. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray Arthritis Rheum. 66 2014 1421 1431 (Hoboken, N.J.)
43. J. Ducreux, P. Durez, C. Galant, A. Nzeusseu Toukap, B. Van den Eynde, F.A. Houssiau, and et al. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium Arthritis Rheum. 66 2014 15 23 (Hoboken, N.J.)
44. M. Dougados, K. Kissel, T. Sheeran, P.P. Tak, P.G. Conaghan, E.M. Mola, and et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Ann. Rheum. Dis. 72 2013 43 50
45. N. Nishimoto, J. Hashimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, and et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab Ann. Rheum. Dis. 66 2007 1162 1167
46. G. Schett, and E. Gravallese Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment Nat. Rev. Rheumatol. 8 2012 656 664
47. F. De Benedetti, N. Rucci, A. Del Fattore, B. Peruzzi, R. Paro, M. Longo, and et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system Arthritis Rheum. 54 2006 3551 3563
48. J. Dai, D. Lin, J. Zhang, P. Habib, P. Smith, J. Murtha, and et al. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice J. Clin. Invest. 106 2000 887 895
49. R. Axmann, C. Bohm, G. Kronke, J. Zwerina, J. Smolen, and G. Schett Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo Arthritis Rheum. 60 2009 2747 2756
50. N. Nishimoto, K. Terao, T. Mima, H. Nakahara, N. Takagi, and T. Kakehi Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease Blood 112 2008 3959 3964
51. K. Shimamoto, T. Ito, Y. Ozaki, H. Amuro, A. Tanaka, T. Nishizawa, and et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis J. Rheumatol. 40 2013 1074 1081
52. R.A. Fava, N.J. Olsen, G. Spencer-Green, K.-T. Yeo, T.-K. Yeo, B. Berse, and et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue J. Exp. Med. 180 1994 341 346
53. A.E. Koch, L.A. Harlow, G.K. Haines, E.P. Amento, E.N. Unemori, W.L. Wong, and et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis J. Immunol. 152 1994 4149 4156
54. M. Nagashima, S. Yoshino, T. Ishikawa, and G. Asano Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis J. Rheumatol. 22 1995 1624 1630
55. T. Kasama, F. Shiozawa, K. Kobayashi, N. Yajima, M. Hanyuda, H.T. Takeuchi, and et al. Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis: critical involvement of the interaction with synovial fibroblasts Arthritis Rheum. 44 2001 2512 2524
56. S. Ballara, P.C. Taylor, P. Reusch, D. Marme, M. Feldmann, R.N. Maini, and et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis Arthritis Rheum. 44 2001 2055 2064
57. H. Nakahara, J. Song, M. Sugimoto, K. Hagihara, T. Kishimoto, K. Yoshizaki, and et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis Arthritis Rheum. 48 2003 1521 1529
58. P. Charles, M.J. Elliott, D. Davis, A. Potter, J.R. Kalden, C. Antoni, and et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis J. Immunol. 163 1999 1521 1528
59. T. Calandra, and T. Roger Macrophage migration inhibitory factor: a regulator of innate immunity Nat. Rev. Immunol. 3 2003 791 800
60. M. Leech, C. Metz, P. Hall, P. Hutchinson, K. Gianis, M. Smith, and et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids Arthritis Rheum. 42 1999 1601 1608
61. E.F. Morand, M. Leech, and J. Bernhagen MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis Nat. Rev. Drug Discov. 5 2006 399 410
62. H.Y. Lan, M. Bacher, N. Yang, W. Mu, D.J. Nikolic-Paterson, C. Metz, and et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat J. Exp. Med. 185 1997 1455 1465
63. M.L. Toh, D. Aeberli, D. Lacey, Y. Yang, L.L. Santos, M. Clarkson, and et al. Regulation of IL-1 and TNF receptor expression and function by endogenous macrophage migration inhibitory factor J. Immunol. 177 2006 4818 4825
64. C.A. Wijbrandts, S.I. van Leuven, H.D. Boom, D.M. Gerlag, E.G. Stroes, J.J. Kastelein, and et al. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis Ann. Rheum. Dis. 68 2009 1316 1321
65. T. Kasama, S. Isojima, M. Umemura, H. Tsukamoto, T. Tokunaga, H. Furuya, and et al. Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis Rheumatol. Int. 34 2014 429 433
66. R. Gomez, J. Conde, M. Scotece, J.J. Gomez-Reino, F. Lago, and O. Gualillo What's new in our understanding of the role of adipokines in rheumatic diseases? Nat. Rev. Rheumatol. 7 2011 528 536
67. X. Chen, J. Lu, J. Bao, J. Guo, J. Shi, and Y. Wang Adiponectin: a biomarker for rheumatoid arthritis? Cytokine Growth Factor Rev. 24 2013 83 89
68. A. Del Prete, V. Salvi, and S. Sozzani Adipokines as potential biomarkers in rheumatoid arthritis Mediat. Inflamm. 2014 2014 425068
69. V. Wittamer, J.D. Franssen, M. Vulcano, J.F. Mirjolet, E. Le Poul, I. Migeotte, and et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids J. Exp. Med. 198 2003 977 985
70. K. Bozaoglu, K. Bolton, J. McMillan, P. Zimmet, J. Jowett, G. Collier, and et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome Endocrinology 148 2007 4687 4694
71. J. Kaur, R. Adya, B.K. Tan, J. Chen, and H.S. Randeva Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis Biochem. Biophys. Res. Commun. 391 2010 1762 1768
72. K. Eisinger, S. Bauer, A. Schaffler, R. Walter, E. Neumann, C. Buechler, and et al. Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis Exp. Mol. Pathol. 92 2012 90 96
73. Y.J. Ha, E.J. Kang, J.S. Song, Y.B. Park, S.K. Lee, and S.T. Choi Plasma chemerin levels in rheumatoid arthritis are correlated with disease activity rather than obesity Joint Bone Spine 81 2014 189 190
74. M.M. Herenius, A.S. Oliveira, C.A. Wijbrandts, D.M. Gerlag, P.P. Tak, and M.C. Lebre Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation PLoS One 8 2013 e57802
75. K. Kaneko, Y. Miyabe, A. Takayasu, S. Fukuda, C. Miyabe, M. Ebisawa, and et al. Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis Arthritis Res. Ther. 13 2011 R158
76. K. Makrilakis, K. Fragiadaki, J. Smith, P.P. Sfikakis, and G.D. Kitas Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade Clin. Rheumatol. 34 2015 419 427
77. T. Hou, B.C. Tieu, S. Ray, A. Recinos Iii, R. Cui, R.G. Tilton, and et al. Roles of IL-6-gp130 signaling in vascular inflammation Curr. Cardiol. Rev. 4 2008 179 192
78. E. Lubberts Role of T lymphocytes in the development of rheumatoid arthritis. Implications for treatment Curr. Pharm. Des. 21 2015 142 146
79. Y. Kochi, Y. Okada, A. Suzuki, K. Ikari, C. Terao, A. Takahashi, and et al. A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility Nat. Genet. 42 2010 515 519
80. A.Y. Lee, and H. Korner CCR6 and CCL20: emerging players in the pathogenesis of rheumatoid arthritis Immunol. Cell Biol. 92 2014 354 358
81. S.Y. Kawashiri, A. Kawakami, N. Iwamoto, K. Fujikawa, T. Aramaki, M. Tamai, and et al. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs J. Rheumatol. 36 2009 2397 2402
82. K. Ozaki, R. Spolski, C.G. Feng, C.F. Qi, J. Cheng, A. Sher, and et al. A critical role for IL-21 in regulating immunoglobulin production Science 298 2002 1630 1634
83. K. Ozaki, R. Spolski, R. Ettinger, H.P. Kim, G. Wang, C.F. Qi, and et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6 J. Immunol. 173 2004 5361 5371
84. R. Ettinger, G.P. Sims, A.M. Fairhurst, R. Robbins, Y.S. da Silva, R. Spolski, and et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells J. Immunol. 175 2005 7867 7879
85. G. Carbone, A. Wilson, S.A. Diehl, J. Bunn, S.M. Cooper, and M. Rincon Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis Int. J. Biol. Sci. 9 2013 279 288
86. E. Matsuura, L.R. Lopez, Y. Shoenfeld, and P.R. Ames Beta2-glycoprotein I and oxidative inflammation in early atherogenesis: a progression from innate to adaptive immunity? Autoimmun. Rev. 12 2012 241 249
87. S. Serada, M. Fujimoto, A. Ogata, F. Terabe, T. Hirano, H. Iijima, and et al. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases Ann. Rheum. Dis. 69 2010 770 774
88. M. Fujimoto, S. Serada, K. Suzuki, A. Nishikawa, A. Ogata, T. Nanki, and et al. Leucine-rich alpha2-glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis Arthritis Rheum. 67 2015 2056 2060 (Hoboken, N.J.)